show episodes
 
Artwork
 
The Chain explores the lives, careers, research, and discoveries of protein engineers and scientists, the impact their work is having on the field, and where the industry is headed. Tune in to stay up-to-date on the newest advancements and to hear the stories that are impacting the world of biologics.
  continue reading
 
Join Gilead-Kite surfing into the future of cell therapy. Listen to Nordic researchers discuss perspectives and future promise of CAR-T in haemato-oncology and solid tumours, CAR-T, TCR, CAR-NK, allo-CAR development and the exciting future of immuno-oncology to combat cancer. Innehållet i podden är skapat av Gilead Sciences Sweden AB, Hemvärnsgatan 9, 171 54 Solna.
  continue reading
 
Watch the best Europeans in biotech to grow. Hosted by Philip Hemme. 10k monthly views. Free. Guests include Antoine Papiernik @Sofinnova, Werner Lanthaler @Evotec, Ingmar Hoerr @CureVac, Bernat Olle @Vedanta, Johannes Fruehauf @BioLabs, Rodger Novak @CRISPR Tx, Agnete Fredriksen @Nykode, Mike Ward, Thomas Clozel @Owkin, Marc de Garidel @Abivax, and Sander van Deventer @VectorY & Forbion. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian ideas.
  continue reading
 
Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.
  continue reading
 
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.
  continue reading
 
Artwork

1
CCO Oncology Podcast

Clinical Care Options

Unsubscribe
Unsubscribe
Monthly+
 
Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
  continue reading
 
As the leading authoritative, peer-reviewed audio source of oncology clinical news for clinicians and healthcare professionals, the AJO Podcast regularly brings you exclusive interviews with the world's leading researchers and clinicians responsible for pushing out the boundaries of science and practice. Medicine, screening, radiotherapy, surgery, clinical trials, cancer care, epidemiology and prevention are covered impartially to give busy cancer professionals access to conversational spoke ...
  continue reading
 
Loading …
show series
 
The mini-protein radiopharmaceutical AKY-1189, designed to deliver the alpha-emitting isotope Actinium-225 (225Ac) to tumors expressing the Nectin-4 transmembrane protein, has been found to achieve favorable dosing to tumors, while minimizing exposure to non-target tissues, including the kidney. Data on the biodistribution and tumor uptake of the d…
  continue reading
 
We’re online with Adrian Rawcliffe, the CEO of Adaptimmune, the TCR cell therapy company behind the first engineered cell therapy for solid tumors that was approved for a rare form of sarcoma. We talked about Tecelra's commercial rollout. We also talked about what's next in cell therapy, and Philly Cheesesteak vs Fish and Chips. — — —Thank you to t…
  continue reading
 
Featuring perspectives from Dr Nicole Lamanna, including the following topics: Introduction (0:00) Case: A man in his late 60s with IGHV-mutated chronic lymphocytic leukemia (CLL) (trisomy 12) and progressive adenopathy — Bhavana (Tina) Bhatnagar, DO (1:22) Case: A woman in her mid 70s with IGHV-unmutated, del(13q) CLL and fatigue — Erik Rupard, MD…
  continue reading
 
Featuring a slide presentation and related discussion from Dr Emanuela Palmerini, including the following topics: Background, diagnosis and disease course of tenosynovial giant cell tumor (TGCT) (0:00) Clinical data supporting systemic therapy for TGCT (10:19) Clinical data on emerging therapies for TGCT (17:28) Conclusion and future directions for…
  continue reading
 
Featuring an interview with Dr Emanuela Palmerini, including the following topics: Pathology, clinical presentation, diagnosis and workup of tenosynovial giant cell tumor (TGCT) (0:00) Local therapies for and surgical management of TGCT (20:28) Available systemic therapies for TGCT (30:31) Investigational agents under development for TGCT (49:13) P…
  continue reading
 
We love to hear from our listeners. Send us a message. Rita Johnson-Greene, COO at Alliance for Regenerative Medicine (ARM) joined Cell & Gene: The Podcast Host, Erin Harris, on site during 2024 Meeting on the Mesa to record their discussion. Johnson-Greene shared information about the Joint Clinical Assessment (JCA) in Europe and its potential imp…
  continue reading
 
Featuring perspectives from Dr Sarah B Goldberg, Dr Brad S Kahl, Dr Sagar Lonial, Dr Joyce O’Shaughnessy, Dr Noopur Raje, Dr Joshua K Sabari, Dr Matthew R Smith, Dr Sonali M Smith, Dr Sandy Srinivas and Dr Seth Wander, including the following topics: Introduction (0:00) Updates in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma — Dr Kahl (1:1…
  continue reading
 
Featuring perspectives from Dr Sarah B Goldberg, Dr Brad S Kahl, Dr Sagar Lonial, Dr Joyce O’Shaughnessy, Dr Noopur Raje, Dr Joshua K Sabari, Dr Matthew R Smith, Dr Sonali M Smith, Dr Sandy Srinivas and Dr Seth Wander, including the following topics: Introduction (0:00) Role of Hormonal Therapy in Prostate Cancer Management — Dr M Smith (10:54) Oth…
  continue reading
 
While existing immunotherapies have changed cancer care, there are several types of cancer where they have limited or no efficacy. Pheast Therapeutics is addressing that by looking to macrophages, part of the innate immune system. These white blood cells gobble up pathogens, cancer cells, and other foreign substances. Certain tumors, though, can ev…
  continue reading
 
The fibroblast growth factor receptor-3 (FGFR-3) inhibitor TYRA-300 has been found safe with dose-dependent responses and disease control in the Phase I SURF301 trial. The study included 41 patients who had been heavily pre-treated for their advanced solid tumors with activating FGFR3 mutations/fusions, bringing the hope of avoiding toxicities from…
  continue reading
 
Featuring perspectives from Dr Komal Jhaveri and Dr Hope S Rugo, including the following topics: Introduction: PI3K/AKT/PTEN Pathway and Resistance to Endocrine Therapy (0:00) First-Line Therapy for HR-Positive Metastatic Breast Cancer (mBC) Harboring PI3K/AKT/PTEN Mutations (7:04) Treatment Options for Recurrent mBC with PI3K/AKT/PTEN Mutations (2…
  continue reading
 
In our first episode recorded live in front of an audience, we’re with Lovisa Afzelius, the General Partner of the European branch of Flagship Pioneering 🇸🇪We talk about Flagship, including its EU activities. We also talk about company-building and Lovisa’s personal journey to be one of the leading Swedish leaders in biotech.⭐️ ABOUT THE SPEAKERLov…
  continue reading
 
Featuring perspectives from Dr Sarah B Goldberg, Dr Brad S Kahl, Dr Sagar Lonial, Dr Joyce O’Shaughnessy, Dr Noopur Raje, Dr Joshua K Sabari, Dr Matthew R Smith, Dr Sonali M Smith, Dr Sandy Srinivas and Dr Seth Wander, including the following topics: Introduction (0:00) Nontargeted Therapy for Lung Cancer — Dr Goldberg (9:07) Targeted Therapy for N…
  continue reading
 
Featuring perspectives from Dr Sarah B Goldberg, Dr Brad S Kahl, Dr Sagar Lonial, Dr Joyce O’Shaughnessy, Dr Noopur Raje, Dr Joshua K Sabari, Dr Matthew R Smith, Dr Sonali M Smith, Dr Sandy Srinivas and Dr Seth Wander, including the following topics: Introduction (0:00) Hormone Receptor-Positive Breast Cancer — Dr O’Shaughnessy (10:45) Management o…
  continue reading
 
In a Phase I study with 318 patients in China and Australia the antibody-drug conjugate (ADC) IBI354 was found to be safe and have promising efficacy in patients whose breast and other solid tumors tested positive for HER2 or were categorized as “HER2-low.” At ESMO Congress 2024, the study also reported a low rate of interstitial lung disease in pa…
  continue reading
 
About 98 percent of the the human genome consists of non-protein coding regions known as the “dark genome.” Once derided as “junk DNA,” these regions are increasingly understood to play a critical role in the regulation of the genome and offer a novel means of targeting diseases. Haya Therapeutics is exploring long non-coding RNAs as potential ther…
  continue reading
 
November 12, 2024 | In this episode of The Chain, host Rakesh Dixit, PhD, DABT, president and founder of Bionavigen Oncology and Regio Biosciences, speaks with Anthony Tolcher, M.D., FRCPC, cofounder of NEXT Oncology, about antibody drug conjugates (ADCs) including the role of the bystander effect, approaching targets in oncology, dual-payload tech…
  continue reading
 
We’re in Budapest with Szabolcs Nagy, the founder of Turbine, one of the leading companies for AI in biotech in the world.We talked about AI in biotech at large. We also cover the differences between opening a platform versus doing proprietary drug development and building the company from central Europe. __This episode is sponsored by Turbine, whi…
  continue reading
 
Loading …

Quick Reference Guide